Navigation Links
WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
Date:5/6/2008

Earnings Conference Call to be held on May 28, 2008 at 8:00 am (Eastern) /

5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong)

SHANGHAI, China, May 6 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it will release unaudited financial results for the first quarter 2008 after the US market close on Tuesday, May 27, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Wednesday, May 28, 2008 to discuss its 2008 first quarter financial results and recent business activity. The conference call may be accessed by calling:

Toll Free Toll

United States +1 718-354-1389

Hong Kong +852 3002-1356

A telephone replay will be available shortly after the call until June 26, 2008 at (US) +1 866-883-4489, +1 718-354-1112 / (HK) +852 3002-1607. Passcode: 5274714#.

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi, Vice President,

Corporate Communications

WuXi PharmaTech Co., Ltd.

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Investor Relations (HK):

Ruby Yim, Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: Pharmatechs@taylor-rafferty.com

Media Contact:

John Dudzinsky, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Honored Among the BCG 50 Local Dynamos
2. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
3. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
4. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
5. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
6. WuXi PharmaTech Completes Acquisition of AppTec
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
9. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
10. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Voice Coil Actuator with a flexure design that ensures high alignment accuracy by ... pricing and is ideally suited where extreme precision is required, such as in ...
(Date:11/30/2016)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... announce the formation of EyGen, Ltd. a new ... through proof of concept. EyGen,s lead asset is ... Limited and being developed for topical ophthalmic delivery ... diseases. This agent has the potential to become ...
(Date:11/30/2016)... Equicare Health Inc ., the leading supplier of comprehensive ... the top 100 companies in the 2016 Global Digital ... top digital health companies across the globe.   ... continually upgrading our product with the ongoing digital shift ... Len Grenier , CEO of Equicare Health, "It,s ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not ... one of the most crucial aspects of recovery so we need to do it ... health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... sleep and find a Christmas present that could help them to manage their sleep ... ...
Breaking Biology News(10 mins):